Cidara Therapeutics (US:CDTX) — Company Overview, News & Financial Data

Cidara Therapeutics logo
CDTXCidara Therapeutics
Cidara Therapeutics primary media

About Cidara Therapeutics

Cidara Therapeutics (NASDAQ:CDTX) is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives to address serious infections. Its innovative pipeline includes lead programs aimed at treating fungal infections, leveraging its proprietary Cloudbreak platform to develop fungicidal agents. Additionally, Cidara is engaged in developing antiviral conjugates through its proprietary technology, aiming to combat challenging viral diseases. With a mission to revolutionize the treatment of infectious diseases and improve patient outcomes, Cidara is dedicated to advancing its pipeline of therapeutics through clinical development to address the unmet needs in infectious disease therapy.

What is CDTX known for?

Snapshot

Public US
Ownership
2012
Year founded
73
Employees
San Diego, United States
Head office
Loading Map...

Operations

All Locations
San Diego, US

Products and/or services of Cidara Therapeutics

  • Rezafungin, a novel antifungal in development for the treatment and prevention of serious fungal infections.
  • Influenza A&B program, utilizing Cloudbreak platform to create antiviral conjugates.
  • CD388, a long-acting therapeutic aimed at seasonal and pandemic influenza prevention.
  • Partnership with Janssen Pharmaceuticals to develop CD377 conjugates, targeting respiratory syncytial virus (RSV).
  • Collaboration with Mundipharma to develop and commercialize rezafungin in select global markets.
  • Research on antiviral conjugates for HIV prevention and treatment using Cloudbreak antiviral platform.

Cidara Therapeutics executive team

  • Dr. Jeffrey L. Stein Ph.D.President, CEO & Executive Director
  • Dr. Leslie Tari Ph.D.Chief Scientific Officer
  • Mr. Frank L. Karbe M.B.A.Chief Financial Officer
  • Mr. Shane M. Ward J.D.COO & Corporate Secretary
  • Ms. Allison Lewis CCP, SPHRSenior Vice President of People & Culture
  • Dr. Nicole Davarpanah J.D., M.D.Chief Medical Officer
  • Mr. Jim Beitel M.B.A.Chief Business Officer
  • Ms. Corrina PavettoSenior Vice President of Clinical Development

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.